TipRanks
Paradigm Biopharmaceuticals Ltd. (PBIGF)
OTHER OTC:PBIGF
US Market
PBIGF
Paradigm Biopharmaceuticals
RESEARCH TOOLSreports

Paradigm Biopharmaceuticals (PBIGF) Ratios

17 Followers

Paradigm Biopharmaceuticals Ratios

PBIGF's free cash flow for Q4 2026 was AU$-0.57. For the 2026 fiscal year, PBIGF's free cash flow was decreased by AU$ and operating cash flow was AU$-714.23. See a summary of the company’s cash flow.
Ratios
TTM
Jun 26Jun 25Jun 24Jun 23
Liquidity Ratios
Current Ratio
 1.10 1.10 7.46 7.22 4.89
Quick Ratio
 1.10 1.10 7.46 7.22 4.89
Cash Ratio
 0.58 0.58 5.20 5.30 4.32
Solvency Ratio
 -2.07 -2.07 -5.53 -16.32 -3.86
Operating Cash Flow Ratio
 -1.64 -1.64 -4.95 -19.63 -3.46
Short-Term Operating Cash Flow Coverage
 -6.11 -6.11 0.00 -541.23 -430.46
Net Current Asset Value
AU$ 2.07MAU$ 2.07MAU$ 20.74MAU$ 20.67MAU$ 50.39M
Leverage Ratios
Debt-to-Assets Ratio
 0.25 0.25 <0.01 <0.01 <0.01
Debt-to-Equity Ratio
 2.16 2.16 <0.01 0.01 <0.01
Debt-to-Capital Ratio
 0.68 0.68 <0.01 <0.01 <0.01
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 8.80 8.80 1.16 1.15 1.25
Debt Service Coverage Ratio
 -5.55 -5.55 -2.64K -429.99 -428.55
Interest Coverage Ratio
 -24.83 -24.83 -3.23K -4.54K -3.61K
Debt to Market Cap
 0.05 0.12 0.00 <0.01 <0.01
Interest Debt Per Share
 0.03 0.03 <0.01 <0.01 <0.01
Net Debt to EBITDA
 0.13 0.13 0.67 0.27 0.95
Profitability Margins
Gross Profit Margin
-102.76%-102.76%-38.17%86.34%-40.26%
EBIT Margin
-76246.47%-76246.47%-48535.61%-98306.99%-126039.35%
EBITDA Margin
-76058.84%-76058.84%-48436.95%-98083.59%-126308.81%
Operating Profit Margin
-76246.47%-76246.47%-43910.60%-99077.51%-126638.15%
Pretax Profit Margin
-79790.11%-79790.11%-48549.19%-89138.30%-126073.57%
Net Profit Margin
-70282.28%-70282.28%-36014.48%-89138.30%-111013.69%
Continuous Operations Profit Margin
-70282.28%-70282.28%-36014.48%-89138.30%-111013.69%
Net Income Per EBT
88.08%88.08%74.18%100.00%88.05%
EBT Per EBIT
104.65%104.65%110.56%89.97%99.55%
Return on Assets (ROA)
-184.36%-184.36%-76.39%-214.14%-77.40%
Return on Equity (ROE)
-1189.87%-1623.03%-88.61%-246.38%-96.71%
Return on Capital Employed (ROCE)
-1538.54%-1538.54%-107.25%-271.29%-109.60%
Return on Invested Capital (ROIC)
-484.07%-484.07%-79.54%-241.23%-96.14%
Return on Tangible Assets
-189.99%-189.99%-77.70%-239.96%-80.95%
Earnings Yield
-66.76%-92.26%-19.57%-68.96%-18.61%
Efficiency Ratios
Receivables Turnover
 <0.01 <0.01 <0.01 0.01 <0.01
Payables Turnover
 <0.01 <0.01 0.03 <0.01 <0.01
Inventory Turnover
 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 0.16 0.16 1.75 0.35 0.14
Asset Turnover
 <0.01 <0.01 <0.01 <0.01 <0.01
Working Capital Turnover Ratio
 0.02 <0.01 <0.01 <0.01 <0.01
Cash Conversion Cycle
 20.97K 20.97K 30.77K -86.37K -182.63K
Days of Sales Outstanding
 59.49K 59.49K 44.64K 28.19K 53.14K
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 38.52K 38.52K 13.86K 114.57K 235.77K
Operating Cycle
 59.49K 59.49K 44.64K 28.19K 53.14K
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.13 -0.12 -0.05 -0.22 -0.16
Free Cash Flow Per Share
 0.00 -0.12 -0.05 -0.22 -0.16
CapEx Per Share
 0.13 0.00 <0.01 0.22 0.00
Free Cash Flow to Operating Cash Flow
 0.00 1.00 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 -1.00 0.00 -3.20M -1.00 0.00
Capital Expenditure Coverage Ratio
 -1.00 0.00 -3.20M -1.00 0.00
Operating Cash Flow Coverage Ratio
 -5.82 -5.82 -2.92K -275.54 -132.25
Operating Cash Flow to Sales Ratio
 -545.06 -545.06 -306.85 -1.00K -966.34
Free Cash Flow Yield
0.00%-71.55%-16.67%-77.53%-16.20%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -1.61 -1.10 -5.11 -1.45 -5.37
Price-to-Sales (P/S) Ratio
 1.83K 761.77 1.84K 1.29K 5.97K
Price-to-Book (P/B) Ratio
 24.31 17.59 4.53 3.57 5.20
Price-to-Free Cash Flow (P/FCF) Ratio
 0.00 -1.40 -6.00 -1.29 -6.17
Price-to-Operating Cash Flow Ratio
 -1.93 -1.40 -6.00 -1.29 -6.17
Price-to-Earnings Growth (PEG) Ratio
 0.02 >-0.01 0.07 -0.13 -0.43
Price-to-Fair Value
 24.31 17.59 4.53 3.57 5.20
Enterprise Value Multiple
 -2.28 -0.87 -3.13 -1.05 -3.77
Enterprise Value
 138.94M 53.19M 79.11M 67.47M 222.95M
EV to EBITDA
 -2.28 -0.87 -3.13 -1.05 -3.77
EV to Sales
 1.73K 663.66 1.52K 1.03K 4.77K
EV to Free Cash Flow
 0.00 -1.22 -4.95 -1.02 -4.93
EV to Operating Cash Flow
 -3.18 -1.22 -4.95 -1.02 -4.93
Tangible Book Value Per Share
 <0.01 <0.01 0.07 0.07 0.18
Shareholders’ Equity Per Share
 0.01 <0.01 0.07 0.08 0.19
Tax and Other Ratios
Effective Tax Rate
 0.12 0.12 0.26 0.10 0.12
Revenue Per Share
 <0.01 <0.01 <0.01 <0.01 <0.01
Net Income Per Share
 -0.16 -0.15 -0.06 -0.20 -0.18
Tax Burden
 0.88 0.88 0.74 1.00 0.88
Interest Burden
 1.05 1.05 1.00 0.91 1.00
Research & Development to Revenue
 672.69 672.69 340.39 886.53 1.13K
SG&A to Revenue
 88.74 88.74 98.33 94.47 140.39
Stock-Based Compensation to Revenue
 0.00 0.00 1.94 0.00 20.03
Income Quality
 0.78 0.78 0.85 1.12 0.87
Currency in AUD